These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 26461173)
1. Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini-review on fundamental concepts and applications. Ferl GZ; Theil FP; Wong H Biopharm Drug Dispos; 2016 Mar; 37(2):75-92. PubMed ID: 26461173 [TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins. Wong H; Chow TW J Pharm Sci; 2017 Sep; 106(9):2270-2275. PubMed ID: 28392453 [TBL] [Abstract][Full Text] [Related]
3. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies. Glassman PM; Balthasar JP J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies. Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465 [TBL] [Abstract][Full Text] [Related]
5. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development. Glassman PM; Balthasar JP Drug Metab Pharmacokinet; 2019 Feb; 34(1):3-13. PubMed ID: 30522890 [TBL] [Abstract][Full Text] [Related]
7. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. Poulin P; Theil FP J Pharm Sci; 2002 May; 91(5):1358-70. PubMed ID: 11977112 [TBL] [Abstract][Full Text] [Related]
8. PBPK models for the prediction of in vivo performance of oral dosage forms. Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672 [TBL] [Abstract][Full Text] [Related]
9. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys. Glassman PM; Chen Y; Balthasar JP J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301 [TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic modeling of nanoparticles. Li M; Al-Jamal KT; Kostarelos K; Reineke J ACS Nano; 2010 Nov; 4(11):6303-17. PubMed ID: 20945925 [TBL] [Abstract][Full Text] [Related]
11. Physiologically based pharmacokinetic (PBPK) modeling of RNAi therapeutics: Opportunities and challenges. Fairman K; Li M; Ning B; Lumen A Biochem Pharmacol; 2021 Jul; 189():114468. PubMed ID: 33577889 [TBL] [Abstract][Full Text] [Related]
12. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. Wang J; Iyer S; Fielder PJ; Davis JD; Deng R Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767 [TBL] [Abstract][Full Text] [Related]
13. Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody. Heiskanen T; Heiskanen T; Kairemo K Curr Pharm Des; 2009; 15(9):988-1007. PubMed ID: 19275663 [TBL] [Abstract][Full Text] [Related]
14. Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits. Bussing D; K Shah D J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):597-612. PubMed ID: 32876799 [TBL] [Abstract][Full Text] [Related]
15. Advances in Physiologically Based Pharmacokinetic (PBPK) Modeling of Nanomaterials. Ozbek O; Genc DE; O Ulgen K ACS Pharmacol Transl Sci; 2024 Aug; 7(8):2251-2279. PubMed ID: 39144562 [TBL] [Abstract][Full Text] [Related]
16. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model. Varkhede N; Forrest ML J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the whole body physiologically based pharmacokinetic (WB-PBPK) modeling of drugs. Munir A; Azam S; Fazal S; Bhatti AI J Theor Biol; 2018 Aug; 451():1-9. PubMed ID: 29704489 [TBL] [Abstract][Full Text] [Related]
18. Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents. Pan X; Stader F; Abduljalil K; Gill KL; Johnson TN; Gardner I; Jamei M AAPS J; 2020 May; 22(4):76. PubMed ID: 32449129 [TBL] [Abstract][Full Text] [Related]
19. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling. Hu S; D'Argenio DZ J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362 [TBL] [Abstract][Full Text] [Related]
20. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach. Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]